| Symbol | VERU |
|---|---|
| Name | VERU INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 48 NW 25TH STREET,SUITE 102, MIAMI, Florida, 33137, United States |
| Telephone | +1 305 509-6897 |
| Fax | — |
| — | |
| Website | https://www.verupharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000863894 |
| Description | Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility, and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Sexual health business and Research & development. Some of its products include Zuclomiphene, Veru-111, Veru-100, FC2, and Roman Swipes. The company generates the majority of its revenue from the United States. Additional info from NASDAQ: |
BARNETTE K GARY 🟢 acquired 1.8K shares of VERU INC. (VERU) at $2.69 Transaction Date: Aug 13, 2026 | Filing ID: 000060
Read moreVeru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
Read moreVeru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
Read moreVeru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
Read moreVeru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
Read moreVeru to Report Fiscal 2026 Third Quarter Financial Results on August 10th
Read moreVeru to Report Fiscal 2026 Third Quarter Financial Results on August 10th
Read moreVeru to Participate in Fireside Chat at the Canaccord Genuitys 46th Annual Growth Investors Conference
Read moreVeru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07446998 | Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety… | Phase2 | Obesity & Overweight | Recruiting | 2026-03-26 | 2027-12-01 | ClinicalTrials.gov |
| NCT06282458 | Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patien… | Phase2 | Muscle Loss | Completed | 2024-04-29 | 2025-08-22 | ClinicalTrials.gov |
| NCT05079360 | Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatm… | Phase2 | Metastatic Breast Cancer | Withdrawn | 2023-03-15 | 2024-05-26 | ClinicalTrials.gov |
| NCT05065411 | Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatmen… | Phase3 | Metastatic Breast Cancer | Terminated | 2022-04-11 | 2024-01-09 | ClinicalTrials.gov |
| NCT05008510 | P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Goviteca… | Phase2 | Metastatic Triple Negative Breast Cancer | Withdrawn | 2021-12-30 | 2023-06-30 | ClinicalTrials.gov |
| NCT04869943 | Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Meta… | Phase3 | Metastatic Breast Cancer | Terminated | 2021-10-12 | 2024-01-09 | ClinicalTrials.gov |
| NCT04844749 | Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least … | Phase3 | Metastatic Castration-resistant Prostate Cancer | Terminated | 2021-06-24 | 2023-05-04 | ClinicalTrials.gov |
| NCT04843319 | To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prosta… | Phase1 | Advanced Prostate Adenocarcinoma | Terminated | 2021-06-09 | 2023-01-19 | ClinicalTrials.gov |
| NCT04842747 | VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on th… | Phase3 | SARS-CoV Infection | Completed | 2021-05-18 | 2022-07-06 | ClinicalTrials.gov |
| NCT04388826 | COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111 | Phase2 | Respiratory Distress Syndrome, Adult | Completed | 2020-06-18 | 2021-08-13 | ClinicalTrials.gov |
| NCT03752099 | To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic… | Phase1 | Metastatic Castration Resistant Prostate Cancer | Terminated | 2019-01-18 | 2023-03-15 | ClinicalTrials.gov |
| NCT03646162 | Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer | Phase2 | Prostate Cancer Metastatic | Completed | 2018-09-14 | 2020-10-15 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Semaglutide (Wegovy) weekly injection | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Enobosarm | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Semaglutide (Wegovy) weekly injection | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Enobosarm | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| VERU-100 | Other | Phase PHASE1 | Advanced Prostate Adenocarcinoma | TERMINATED | NCT04843319 |
| Placebo | Other | Phase PHASE2 | Prostate Cancer Metastatic | COMPLETED | NCT03646162 |
| Veru-944 | Other | Phase PHASE2 | Prostate Cancer Metastatic | COMPLETED | NCT03646162 |
| Sabizabulin/Sacituzumab govitecan-hziy Combo | Other | Phase PHASE2 | Metastatic Triple Negative Breast Cancer | WITHDRAWN | NCT05008510 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE2 | Metastatic Triple Negative Breast Cancer | WITHDRAWN | NCT05008510 |
| Sabizabulin | Other | Phase PHASE2 | Metastatic Triple Negative Breast Cancer | WITHDRAWN | NCT05008510 |
| Veru-111 | Other | Phase PHASE2 | Respiratory Distress Syndrome, Adult | COMPLETED | NCT04388826 |
| Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator | Drug | Phase PHASE2 | Metastatic Breast Cancer | WITHDRAWN | NCT05079360 |
| Sabizabulin | Other | Phase PHASE2 | Metastatic Breast Cancer | WITHDRAWN | NCT05079360 |
| VERU-111 | Other | Phase PHASE3 | SARS-CoV Infection | COMPLETED | NCT04842747 |
| VERU-111 | Other | Phase PHASE1 | Metastatic Castration Resistant Prostate Cancer | TERMINATED | NCT03752099 |
| Exemestane | Other | Phase PHASE3 | Metastatic Breast Cancer | TERMINATED | NCT04869943 |
| Enobosarm | Other | Phase PHASE3 | Metastatic Breast Cancer | TERMINATED | NCT04869943 |
| Enzalutamide, Abiraterone | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT04844749 |
| VERU-111 | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT04844749 |
| non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant | Other | Phase PHASE3 | Metastatic Breast Cancer | TERMINATED | NCT05065411 |
| Enobosarm & Abemaciclib Combo | Other | Phase PHASE3 | Metastatic Breast Cancer | TERMINATED | NCT05065411 |
| Semaglutide | Other | Phase PHASE2 | Muscle Loss | COMPLETED | NCT06282458 |
| Enobosarm | Other | Phase PHASE2 | Muscle Loss | COMPLETED | NCT06282458 |
| Semaglutide (Wegovy) weekly injection | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Enobosarm | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Semaglutide (Wegovy) weekly injection | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Enobosarm | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Semaglutide (Wegovy) weekly injection | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Enobosarm | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Semaglutide (Wegovy) weekly injection | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Enobosarm | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Semaglutide (Wegovy) weekly injection | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Enobosarm | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Semaglutide (Wegovy) weekly injection | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Enobosarm | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Semaglutide (Wegovy) weekly injection | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Enobosarm | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Semaglutide (Wegovy) weekly injection | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Enobosarm | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Semaglutide (Wegovy) weekly injection | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Enobosarm | Other | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Semaglutide (Wegovy) weekly injection | DRUG | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Semaglutide | DRUG | Phase PHASE2 | Muscle Loss | COMPLETED | NCT06282458 |
| Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator | DRUG | Phase PHASE2 | Metastatic Breast Cancer | WITHDRAWN | NCT05079360 |
| non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant | DRUG | Phase PHASE3 | Metastatic Breast Cancer | TERMINATED | NCT05065411 |
| Enobosarm & Abemaciclib Combo | DRUG | Phase PHASE3 | Metastatic Breast Cancer | TERMINATED | NCT05065411 |
| Sabizabulin/Sacituzumab govitecan-hziy Combo | DRUG | Phase PHASE2 | Metastatic Triple Negative Breast Cancer | WITHDRAWN | NCT05008510 |
| Sacituzumab Govitecan-hziy | DRUG | Phase PHASE2 | Metastatic Triple Negative Breast Cancer | WITHDRAWN | NCT05008510 |
| Sabizabulin | DRUG | Phase PHASE2 | Metastatic Breast Cancer | WITHDRAWN | NCT05079360 |
| Exemestane | DRUG | Phase PHASE3 | Metastatic Breast Cancer | TERMINATED | NCT04869943 |
| Enobosarm | DRUG | Phase PHASE2 | Obesity & Overweight | RECRUITING | NCT07446998 |
| Enzalutamide, Abiraterone | DRUG | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT04844749 |
| VERU-100 | DRUG | Phase PHASE1 | Advanced Prostate Adenocarcinoma | TERMINATED | NCT04843319 |
| Veru-111 | DRUG | Phase PHASE2 | Respiratory Distress Syndrome, Adult | COMPLETED | NCT04388826 |
| VERU-111 | DRUG | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT04844749 |
| Placebo | DRUG | Phase PHASE2 | Prostate Cancer Metastatic | COMPLETED | NCT03646162 |
| Veru-944 | DRUG | Phase PHASE2 | Prostate Cancer Metastatic | COMPLETED | NCT03646162 |